Sculptor Capital LP Purchases New Holdings in Kenvue Inc. $KVUE

Sculptor Capital LP purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,052,467 shares of the company’s stock, valued at approximately $77,443,000. Sculptor Capital LP owned approximately 0.21% of Kenvue as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Johnson Financial Group Inc. acquired a new position in Kenvue during the second quarter worth $26,000. CoreCap Advisors LLC lifted its stake in Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after acquiring an additional 591 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Kenvue in the fourth quarter valued at $26,000. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the period. Finally, MV Capital Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth about $28,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 0.4%

Shares of KVUE opened at $19.34 on Wednesday. The firm has a market cap of $37.16 billion, a P/E ratio of 22.24, a price-to-earnings-growth ratio of 1.39 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $21.40. The firm’s 50-day simple moving average is $19.10 and its 200 day simple moving average is $18.22.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the prior year, the firm earned $0.29 EPS. The company’s revenue was up 3.0% on a year-over-year basis. On average, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Wednesday, August 12th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 96.55%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KVUE. Barclays upped their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, UBS Group cut their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.